Skip to content

TYRA BIOSCIENCES, INC.

US · TYRA #3032 by market cap Listed 2021
20.12 +0.39 +1.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 19.63 -0.51%
After-hours 20.29 +0.84%
33.5918.5220.122026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TYRA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -12.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 14.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -39.8% Better than 10%
Return on invested capital -43.2% Better than 7%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.8% Better than 26%
6-month return -38.0% Better than 13%
12-month return (ex latest month) -3.2% Better than 30%
Distance below 52-week high 50.5% Better than 18%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.7x Better than 96%
Debt to assets 2.1% Better than 88%
Interest coverage -9,335.0x Better than 1%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 137.5% Better than 89%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +0.47%
1M -1.71%
3M -21.68%
6M -39.76%
YTD -23.47%
1Y -4.19%
3Y +78.53%
5Y -16.17%

Key statistics

Price & volume

Prev close
19.73
Open
19.62
Day range
19.48 - 20.44
Avg price
20.05
Volume
467.58K
Turnover
9.38M
Amplitude
4.89%
52-week range
18.25 - 40.65

Valuation

P/E
-10.01
P/E (TTM)
-7.65
P/B
2.01
EPS
-2.01
Net profit
-138.86M
Net assets
692.83M

Share structure

Market cap
1.39B
Float cap
810.64M
Shares out
69.08M
Float shares
40.29M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-09-15
52-week range 8% of range
18.25 40.65

50.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+1.53M net over the window

Short interest

Shares short
9.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of TYRA BIOSCIENCES, INC. (TYRA)?

TYRA BIOSCIENCES, INC. last traded at 20.12. This page shows a periodic quote snapshot. Check the displayed quote time.

What is TYRA BIOSCIENCES, INC.'s market cap?

About 1.39B.

What is the P/E ratio of TYRA BIOSCIENCES, INC.?

The trailing twelve-month P/E is -7.65. The Valuation tab shows it against the stock's own five-year range.

Does TYRA BIOSCIENCES, INC. pay a dividend?

TYRA BIOSCIENCES, INC. does not currently pay a regular dividend.

Is TYRA BIOSCIENCES, INC. a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 47.78, which implies 137.5% upside from the current price. This is not investment advice.

What is TYRA BIOSCIENCES, INC.'s StockVane Quant Rating?

The StockVane Momentum strategy currently rates TYRA BIOSCIENCES, INC. a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

TYRA BIOSCIENCES, INC. discussion 0 comments

Add a comment